Answers are grounded in this paper and cite their sources.
The addition of bevacizumab to gemcitabine does not improve survival in advanced pancreatic cancer patients.
No takes yet. Share an insight, caveat, or question.
Kindler et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: